These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 33545279)

  • 1. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model.
    Zhang H; Almuqbil RM; Alhudaithi SS; Sunbul FS; da Rocha SRP
    Int J Pharm; 2021 Apr; 598():120350. PubMed ID: 33545279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
    Alhudaithi SS; Almuqbil RM; Zhang H; Bielski ER; Du W; Sunbul FS; Bos PD; da Rocha SRP
    Mol Pharm; 2020 Dec; 17(12):4691-4703. PubMed ID: 33170724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Antigen-Primed Dendritic Cell-Derived Exosome Synergizes with Colony Stimulating Factor-1 Receptor Inhibitor by Modulating the Tumor Microenvironment and Systemic Immunity.
    Barnwal A; Gaur V; Sengupta A; Tyagi W; Das S; Bhattacharyya J
    ACS Biomater Sci Eng; 2023 Nov; 9(11):6409-6424. PubMed ID: 37870457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer.
    Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
    Eur J Pharm Sci; 2023 Jun; 185():106427. PubMed ID: 36948408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of tumor-associated macrophages inhibits lung cancer growth and enhances the antitumor effect of cisplatin.
    Kawaguchi Y; Ohshio Y; Watanabe A; Shiratori T; Okamoto K; Ueda K; Kataoka Y; Suzuki T; Hanaoka J
    Cancer Sci; 2023 Mar; 114(3):750-763. PubMed ID: 36411518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer.
    Lu CS; Shiau AL; Su BH; Hsu TS; Wang CT; Su YC; Tsai MS; Feng YH; Tseng YL; Yen YT; Wu CL; Shieh GS
    J Hematol Oncol; 2020 Jun; 13(1):62. PubMed ID: 32487125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
    Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
    J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
    Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
    Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
    Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
    Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
    Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
    Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin.
    Pass HI; Lavilla C; Canino C; Goparaju C; Preiss J; Noreen S; Blandino G; Cioce M
    Oncotarget; 2016 Aug; 7(35):56408-56421. PubMed ID: 27486763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy.
    Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
    Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF-1R inhibition alters macrophage polarization and blocks glioma progression.
    Pyonteck SM; Akkari L; Schuhmacher AJ; Bowman RL; Sevenich L; Quail DF; Olson OC; Quick ML; Huse JT; Teijeiro V; Setty M; Leslie CS; Oei Y; Pedraza A; Zhang J; Brennan CW; Sutton JC; Holland EC; Daniel D; Joyce JA
    Nat Med; 2013 Oct; 19(10):1264-72. PubMed ID: 24056773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of tumor-associated macrophages in lung cancer: From mechanism to small molecule therapy.
    Zhou Y; Qian M; Li J; Ruan L; Wang Y; Cai C; Gu S; Zhao X
    Biomed Pharmacother; 2024 Jan; 170():116014. PubMed ID: 38134634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
    Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
    Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.
    Valero JG; Matas-Céspedes A; Arenas F; Rodriguez V; Carreras J; Serrat N; Guerrero-Hernández M; Yahiaoui A; Balagué O; Martin S; Capdevila C; Hernández L; Magnano L; Rivas-Delgado A; Tannheimer S; Cid MC; Campo E; López-Guillermo A; Colomer D; Pérez-Galán P
    Leukemia; 2021 Sep; 35(9):2635-2649. PubMed ID: 33731849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
    Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
    Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemotherapy Induces IL34 Signaling and Promotes Chemoresistance via Tumor-Associated Macrophage Polarization in Esophageal Squamous Cell Carcinoma.
    Nakajima S; Mimura K; Saito K; Thar Min AK; Endo E; Yamada L; Kase K; Yamauchi N; Matsumoto T; Nakano H; Kanke Y; Okayama H; Saito M; Neupane P; Saze Z; Watanabe Y; Hanayama H; Hayase S; Kaneta A; Momma T; Ohki S; Ohira H; Kono K
    Mol Cancer Res; 2021 Jun; 19(6):1085-1095. PubMed ID: 33674443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M1
    Garrido-Martin EM; Mellows TWP; Clarke J; Ganesan AP; Wood O; Cazaly A; Seumois G; Chee SJ; Alzetani A; King EV; Hedrick CC; Thomas G; Friedmann PS; Ottensmeier CH; Vijayanand P; Sanchez-Elsner T
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32699181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.